Biohaven (BHVN) Income from Continuing Operations (2021 - 2026)
Biohaven (BHVN) posted Income from Continuing Operations of 130532000.0 for Q1 2026, up 10.32% sequentially from 145555000.0 in Q4 2025, and up 41.12% YoY from 92499703.23 in Q1 2025.
Biohaven (BHVN) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Biohaven has reported Income from Continuing Operations for 6 years, with the latest figure at 130532000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 41.12% year-over-year to 130532000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 647677000.0 (up 27.11% YoY) and the FY2025 annual result came in at 738822000.0, up 12.71% from the prior year.
- Income from Continuing Operations advanced to 130532000.0 in Q1 2026 per BHVN's latest filing, from 145555000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 68853000.0 in Q3 2022 and troughed at 319771000.0 in Q2 2024.
- A 5-year average of 158483705.88 and a median of 160304000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations slumped 287.59% in 2022, then surged 55.56% in 2023.
- Over 5 years, Income from Continuing Operations stood at 201107000.0 in 2022, then grew by 28.02% to 144756000.0 in 2023, then slipped by 29.07% to 186843000.0 in 2024, then increased by 22.1% to 145555000.0 in 2025, then increased by 10.32% to 130532000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 130532000.0, 145555000.0, and 173443000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Biohaven | 2.21 Bn | 1.94 Bn | - | -137.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -137.31 Mn |
| Mar 31, 2026 | -130.53 Mn |
| Dec 31, 2025 | -145.56 Mn |
| Sep 30, 2025 | -173.44 Mn |
| Jun 30, 2025 | -198.15 Mn |
| Mar 31, 2025 | -221.68 Mn |
| Dec 31, 2024 | -186.84 Mn |
| Sep 30, 2024 | -160.30 Mn |
| Jun 30, 2024 | -319.77 Mn |
| Mar 31, 2024 | -179.50 Mn |
| Dec 31, 2023 | -144.76 Mn |
| Sep 30, 2023 | -102.57 Mn |
| Jun 30, 2023 | -90.35 Mn |
| Mar 31, 2023 | -70.49 Mn |
| Dec 31, 2022 | -201.11 Mn |
| Sep 30, 2022 | -68.85 Mn |
| Jun 30, 2022 | -203.29 Mn |
| Mar 31, 2022 | -97.03 Mn |
| Dec 31, 2021 | -51.89 Mn |
| Sep 30, 2021 | -54.37 Mn |